Prognostic Significance and Immune Landscape of an Efferocytosis-Related Gene Signature in Bladder Cancer

Overview

Journal Biochem Genet

Specialty Molecular Biology

Date 2024 Sep 23

PMID 39313721

Authors

Fuchun Zheng

Zhipeng Wang

Qianxi Dong

Sheng Li

Situ Xiong

Yuyang Yuan

Songhui Xu

Bin Fu

Affiliations

Soon will be listed here.

Abstract

Bladder cancer poses a significant global health challenge, underscoring the imperative for precise prognostic instruments to advance patient care. Against the backdrop of efferocytosis's increasingly recognized role in cancer, this research endeavors to develop and authenticate a prognostic signature intricately linked to efferocytosis in bladder cancer. LASSO-COX regression analysis crafted an efferocytosis-related genes risk prognostic model, followed by the construction of a column chart. External validation sets confirmed the predictive accuracy of both the model and chart. Clinical, tumor microenvironment, drug sensitivity, and immunotherapy analyses were employed to comprehensively assess efferocytosis-related scores. The expression of TGFB3 key genes was validated via RT-PCR and western blotting. Further validation included Transwell, Wound healing, Colony formation, and EDU assays. We formulated and validated an efferocytosis-related genes risk model in bladder cancer, comprising 13 core genes. The risk model demonstrated autonomous prognostic significance in both univariate and multivariate Cox analyses. Following the multivariate analysis, we devised a nomogram. Moreover, by utilizing individual risk scores derived from this risk model, we successfully stratified patients into two discernible risk cohorts, unveiling noteworthy variances in immune infiltration profiles and responsiveness to immunotherapy. Notably, the model's key gene TGFB3 was validated through comprehensive experimental investigations, including Transwell assays for migration and invasion and Wound healing assays for motility on the T24 and BIU cell lines. This study has furnished innovative perspectives on an efferocytosis-related prognostic signature, elucidating the prognosis and immune milieu intricacies in patients with bladder cancer.

References

Al Kafri N, Hafizi S . Tumour-Secreted Protein S (ProS1) Activates a Tyro3-Erk Signalling Axis and Protects Cancer Cells from Apoptosis. Cancers (Basel). 2019; 11(12). PMC: 6966665. DOI: 10.3390/cancers11121843. View

An B, Guo Z, Wang J, Zhang C, Zhang G, Yan L . Derivation and external validation of dendritic cell-related gene signatures for predicting prognosis and immunotherapy efficacy in bladder urothelial carcinoma. Front Immunol. 2022; 13:1080947. PMC: 9790929. DOI: 10.3389/fimmu.2022.1080947. View

Beckham C, Olsen J, Yin P, Wu C, Ting H, Hagen F . Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. J Urol. 2014; 192(2):583-92. DOI: 10.1016/j.juro.2014.02.035. View

Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L . Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11):1015-1026. PMC: 5635424. DOI: 10.1056/NEJMoa1613683. View

Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

Chaudhary S, Patidar A, Dhiman A, Chaubey G, Dilawari R, Talukdar S . Exposure of a specific pleioform of multifunctional glyceraldehyde 3-phosphate dehydrogenase initiates CD14-dependent clearance of apoptotic cells. Cell Death Dis. 2021; 12(10):892. PMC: 8482365. DOI: 10.1038/s41419-021-04168-8. View

Chouhan S, Sawant M, Weimholt C, Luo J, Sprung R, Terrado M . TNK2/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of prostate cancer while engendering mitochondrial vulnerability. Autophagy. 2022; 19(3):1000-1025. PMC: 9980697. DOI: 10.1080/15548627.2022.2103961. View

Fu J, Zhang W, Jiang T . Immunogenic cell death mediation patterns reveal novel paradigm for characterizing the immune microenvironment and immunotherapeutic responses in bladder cancer. Front Genet. 2022; 13:1035484. PMC: 9640952. DOI: 10.3389/fgene.2022.1035484. View

Gao J, Zhu Y, Nilsson M, Sundfeldt K . TGF-β isoforms induce EMT independent migration of ovarian cancer cells. Cancer Cell Int. 2014; 14(1):72. PMC: 4180856. DOI: 10.1186/s12935-014-0072-1. View

10.

Hanson I, Pitman K, Edin N . The Role of TGF-β3 in Radiation Response. Int J Mol Sci. 2023; 24(8). PMC: 10141893. DOI: 10.3390/ijms24087614. View

11.

Henson P . Cell Removal: Efferocytosis. Annu Rev Cell Dev Biol. 2017; 33:127-144. DOI: 10.1146/annurev-cellbio-111315-125315. View

12.

Ji Y, Zuo C, Liao N, Yao L, Yang R, Chen H . Identification of key lncRNAs in age-related macular degeneration through integrated bioinformatics and experimental validation. Aging (Albany NY). 2024; 16(6):5435-5451. PMC: 11006464. DOI: 10.18632/aging.205656. View

13.

Lecoultre M, Dutoit V, Walker P . Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review. J Immunother Cancer. 2020; 8(2). PMC: 7747550. DOI: 10.1136/jitc-2020-001408. View

14.

Lee Y, Lee M, De Silva D, Roy A, Wright C, Wong T . Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. PLoS One. 2021; 16(7):e0241766. PMC: 8297783. DOI: 10.1371/journal.pone.0241766. View

15.

Liu J, Kong C, Gong D, Zhang Z, Zhu Y . PKC α regulates netrin-1/UNC5B-mediated survival pathway in bladder cancer. BMC Cancer. 2014; 14:93. PMC: 3937025. DOI: 10.1186/1471-2407-14-93. View

16.

Liu M, OConnor R, Trefely S, Graham K, Snyder N, Beatty G . Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. Nat Immunol. 2019; 20(3):265-275. PMC: 6380920. DOI: 10.1038/s41590-018-0292-y. View

17.

Lv Z, Gao W, Du Z, Zheng Y, Liu T, Hao C . Alternative splicing of IRF3 plays an important role in the development of hepatocarcinoma. Epigenetics. 2023; 18(1):2276371. PMC: 10629432. DOI: 10.1080/15592294.2023.2276371. View

18.

Ma J, Hu J, Zhao L, Wu Z, Li R, Deng W . Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment. BMC Urol. 2024; 24(1):6. PMC: 10765654. DOI: 10.1186/s12894-023-01354-y. View

19.

Mehrotra P, Ravichandran K . Drugging the efferocytosis process: concepts and opportunities. Nat Rev Drug Discov. 2022; 21(8):601-620. PMC: 9157040. DOI: 10.1038/s41573-022-00470-y. View

20.

Murdoch C, Muthana M, Coffelt S, Lewis C . The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008; 8(8):618-31. DOI: 10.1038/nrc2444. View